Biktarvy
Study Finds 1 INSTI Combo Fares Better With Weight Gain
How do you pick which drug to prescribe for your patients with HIV?
MARCH 26, 2025
Good Results With Biktarvy in HIV–HBV Coinfection
At CROI 2025, Dr. Anchalee Avihingsanon and her colleagues reported Week 48 outcomes from the open-label extension ...
MARCH 25, 2025
Biktarvy’s Benefits Extend in Older Adults With HIV
Five-year follow-up data from the triple combination HIV therapy bictegravir-emtricitabine-tenofavir alafenamide ...
NOVEMBER 26, 2024
FDA Approves Biktarvy Label Update With Data for Use During Pregnancy
The FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy for ...
APRIL 30, 2024
FDA Expands Indication of Biktarvy for Resistant HIV
The FDA expanded the indication for bictegravir-emtricitabine-tenofovir alafenamide (B/F/TAF; Biktarvy, Gilead) to ...
FEBRUARY 29, 2024
Biktarvy a Long-Term Option for Older Adults With HIV
Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) could be a long-term option for ...
DECEMBER 9, 2022
Biktarvy Shows Durable Viral Suppression After 5 Years
Five-year cumulative data from two trials of Biktarvy demonstrated high rates of viral suppression that were ...
AUGUST 3, 2022
Counterfeit HIV Meds Found in the U.S.
Gilead Sciences warned that tampered and counterfeit versions of its HIV medications, Biktarvy and Descovy, are in ...
AUGUST 10, 2021
Switching to Biktarvy Appears Effective for Blacks With HIV
Bictegravir-emtricitabine-tenofovir alafenamide can control viral loads in Black Americans with HIV, even among ...
NOVEMBER 10, 2020
New ART Suppresses HIV in Treatment-Experienced Adults
High rates of virologic suppression were seen in treatment-experienced adults who switched to BIC/FTC/TAF, ...
MARCH 27, 2019
Biktarvy Demonstrates High Efficacy, Tolerability Through 96 Weeks
Gilead reported 96 week results for a comparative trial of Biktarvy in HIV patients who were treatment naive.
OCTOBER 9, 2018
Switching HIV Regimen Found Safe
Switching to the newly approved Biktarvy in virologically suppressed adults maintained viral suppression with fewer ...
MARCH 7, 2018
